FDA Expands Use of Orkambi® to Children Ages 6 to 11 With CF
September 28, 2016
The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.